About Sunesis Pharmaceuticals (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:SNSS
- CUSIP: 86732860
- Web: www.sunesis.com
Capitalization:- Market Cap: $51.26 million
- Outstanding Shares: 23,513,000
Average Prices:- 50 Day Moving Avg: $2.14
- 200 Day Moving Avg: $2.78
- 52 Week Range: $1.84 - $4.53
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.57
- P/E Growth: -0.01
Sales & Book Value:- Annual Revenue: $1.96 million
- Price / Sales: 26.15
- Book Value: ($0.27) per share
- Price / Book: -8.07
Profitability:- EBITDA: ($34,640,000.00)
- Net Margins: -1,472.94%
- Return on Assets: -112.07%
Debt:- Current Ratio: 3.36%
- Quick Ratio: 3.36%
Misc:- Average Volume: 116,136 shs.
- Beta: 1.52
- Short Ratio: 5.5
Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its quarterly earnings data on Thursday, July, 27th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.35. During the same period in the previous year, the company earned ($0.12) EPS. View Sunesis Pharmaceuticals' Earnings History.
When will Sunesis Pharmaceuticals make its next earnings announcement?
Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?
2 brokers have issued 1 year price objectives for Sunesis Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' stock price to reach $3.00 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.
What are analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (10/4/2017)
- 2. Cantor Fitzgerald analysts commented, "Interim data analysis from Phase Ib study of BTK inhibitor SNS-062 is expected in mid-2018, possibly at ASCO." (9/27/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Galectin Therapeutics (GALT), Tissue Regenix Group PLC (TRX), ArQule (ARQL), Brainstorm Cell Therapeutics (BCLI), Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Vernalis plc (VER), CytRx Corporation (CYTR), Prima BioMed Ltd (PBMD), ReNeuron Group Plc (RENE), OvaScience (OVAS), Genocea Biosciences (GNCA), Bio-Path Holdings (BPTH), Abzena PLC (ABZA), Senomyx (SNMX), Scancell Holdings Plc (SCLP) and Fibrocell Science (FCSC).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Daniel N. Swisher Jr., President, Chief Executive Officer, Director
- Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer
- James W. Young Ph.D., Non-Executive Independent Chairman of the Board
- Stephen B. Ketchum Ph.D., Director
- Geoffrey M. Parker, Director
- Steve R Carchedi, Independent Director
- Matthew K. Fust, Independent Director
How do I buy Sunesis Pharmaceuticals stock?
Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $2.18.
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.41) | | | | | N/A |  |
| 7/27/2017 | Q2 2017 | ($0.76) | ($0.41) | $2.40 million | | View | N/A | |
| 5/8/2017 | Q1 2017 | ($0.83) | ($0.47) | $1.57 million | $0.67 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.43) | ($0.44) | $0.60 million | $0.68 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.71) | ($0.62) | $0.60 million | $0.60 million | View | N/A | |
| 7/29/2016 | Q216 | ($0.10) | ($0.12) | $0.70 million | $0.60 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.12) | ($0.12) | $0.77 million | $0.64 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.14) | ($0.15) | $0.84 million | $0.67 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.12) | ($0.09) | $1.09 million | $0.68 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.13) | ($0.15) | $1.21 million | $0.85 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.16) | ($0.13) | $1.14 million | $0.90 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.20) | ($0.02) | $1.17 million | $0.90 million | View | Listen | |
| 11/10/2014 | Q314 | ($0.17) | ($0.25) | $1.97 million | $0.85 million | View | Listen | |
| 8/5/2014 | Q214 | ($0.17) | ($0.20) | $1.32 million | $2.00 million | View | Listen | |
| 5/7/2014 | Q114 | ($0.17) | ($0.26) | $1.32 million | $2.00 million | View | Listen | |
| 3/6/2014 | Q413 | ($0.20) | ($0.15) | $1.37 million | $2.00 million | View | Listen | |
| 11/12/2013 | Q313 | ($0.20) | ($0.16) | $1.44 million | $1.99 million | View | Listen | |
| 7/29/2013 | Q2 2013 | ($0.21) | $0.18 | $1.22 million | $1.99 million | View | Listen | |
| 5/9/2013 | Q1 2013 | ($0.20) | ($0.23) | $0.75 million | $1.99 million | View | Listen | |
| 3/13/2013 | Q4 2012 | ($0.19) | ($0.20) | $0.32 million | $1.99 million | View | Listen | |
| 11/8/2012 | Q312 | ($0.11) | ($0.37) | $4.17 million | $0.26 million | View | N/A | |
| 8/9/2012 | | ($0.20) | ($0.20) | | | View | N/A | |
| 5/15/2012 | | ($0.18) | ($0.30) | | | View | N/A | |
| 11/14/2011 | | ($0.18) | ($0.11) | | | View | N/A | |
| 8/11/2011 | | ($0.15) | ($0.18) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS
Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 57.54%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/9/2016 | Geoffrey M Parker | Director | Buy | 3,740 | $3.87 | $14,473.80 | |
| 5/26/2016 | Geoffrey M Parker | Director | Buy | 9,500 | $0.47 | $4,465.00 | |
| 5/25/2016 | Geoffrey M Parker | Director | Buy | 52,505 | $0.47 | $24,677.35 | |
| 12/21/2015 | Dayton Misfeldt | Director | Buy | 1,750,000 | $0.84 | $1,470,000.00 | |
| 8/25/2015 | Daniel N Swisher Jr | CEO | Buy | 12,216 | $1.01 | $12,338.16 | |
| 8/24/2015 | Daniel N Swisher Jr | CEO | Buy | 12,784 | $1.01 | $12,911.84 | |
| 8/29/2014 | Forest Baskett | Major Shareholder | Sell | 266,700 | $7.97 | $2,125,599.00 | |
| 8/28/2014 | Bay City Capital Llc | Major Shareholder | Sell | 300,700 | $7.98 | $2,399,586.00 | |
| 8/28/2014 | Dayton Misfeldt | Director | Sell | 200,000 | $7.89 | $1,578,000.00 | |
| 8/27/2014 | Adam R Craig | CMO | Sell | 2,554 | $8.00 | $20,432.00 | |
| 8/27/2014 | Daniel N Swisher Jr | CEO | Sell | 5,000 | $8.00 | $40,000.00 | |
| 8/27/2014 | Dayton Misfeldt | Director | Sell | 100,700 | $8.16 | $821,712.00 | |
| 8/27/2014 | Eric Bjerkholt | CFO | Sell | 10,000 | $8.00 | $80,000.00 | |
| 8/27/2014 | Krishna Kittu Kolluri | Major Shareholder | Sell | 108,300 | $8.17 | $884,811.00 | |
| 8/12/2014 | Dayton Misfeldt | Director | Sell | 743,700 | $6.64 | $4,938,168.00 | |
| 8/12/2014 | Equity Opportunities Fu Growth | Major Shareholder | Sell | 710,540 | $6.63 | $4,710,880.20 | |
(Data available from 1/1/2013 forward)
Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
| Source: |
|
| Date | Headline |
|---|
 | -$0.25 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - October 12 at 2:28 PM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 8 at 6:40 PM |
 | Sunesis Pharmaceuticals (SNSS) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 29 at 6:38 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Given "Hold" Rating at Cantor Fitzgerald
www.americanbankingnews.com - September 27 at 4:16 PM |
| -$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - September 23 at 8:28 PM |
| Sunesis Pharmaceuticals (SNSS) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 9 at 8:41 AM |
| Sunesis Pharmaceuticals: SNS-062 Could Be The Company's Salvation - Seeking Alpha
seekingalpha.com - August 31 at 10:17 AM |
 | Sunesis to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - August 31 at 10:17 AM |
 | Sunesis to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 10:17 AM |
| FY2017 EPS Estimates for Sunesis Pharmaceuticals, Inc. Increased by Cantor Fitzgerald (SNSS)
www.americanbankingnews.com - August 3 at 9:30 AM |
| Sunesis Pharmaceuticals' (SNSS) CEO Dan Swisher on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 1 at 4:03 PM |
 | Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - July 29 at 7:22 AM |
| Sunesis reports 2Q loss
finance.yahoo.com - July 28 at 8:09 AM |
| Edited Transcript of SNSS earnings conference call or presentation 27-Jul-17 6:00pm GMT
finance.yahoo.com - July 28 at 8:09 AM |
| Cantor Fitzgerald Reiterates "Hold" Rating for Sunesis Pharmaceuticals, Inc. (SNSS)
www.americanbankingnews.com - July 27 at 9:43 PM |
| Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Posts Earnings Results, Beats Expectations By $0.35 EPS
www.americanbankingnews.com - July 27 at 5:20 PM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - July 27 at 7:39 AM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - July 27 at 7:39 AM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - July 27 at 7:39 AM |
| Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - July 27 at 7:39 AM |
 | Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights
feeds.benzinga.com - July 24 at 7:38 AM |
| Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 7:56 AM |
| Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:42 AM |
| Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies
finance.yahoo.com - July 18 at 8:48 PM |
| Sunesis Pharmaceuticals (SNSS) vs. Biohaven Pharmaceutical Holding Co (BHVN) Critical Analysis
www.americanbankingnews.com - July 17 at 9:55 AM |
| -$0.76 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - July 6 at 7:36 AM |
| Sunesis Pharmaceuticals Added to Russell Microcap® Index - GlobeNewswire (press release)
globenewswire.com - June 27 at 8:01 PM |
 | Sunesis Pharmaceuticals (SNSS) Announces Presentation of ... - StreetInsider.com
www.streetinsider.com - June 24 at 6:51 AM |
| Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:25 PM |
 | Sunesis reports 1Q loss
marketbeat.com - May 8 at 7:06 AM |
 | INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
www.businesswire.com - May 3 at 11:07 PM |
| Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA)
www.nasdaq.com - May 3 at 10:45 AM |
| BUZZ-U.S. STOCKS ON THE MOVE-Angie's List, Tenet, Chegg, AMD, Coach, Merck, Sunesis Pharma - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM |
| AZN Gets FDA Nod, CORT Boosts Outlook Yet Again, SNSS Withdraws Vosaroxin MAA - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM |
| Sunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $3 at Cantor Fitzgerald Following MAA Withdrawl - StreetInsider.com
www.streetinsider.com - May 2 at 9:21 AM |
| Sunesis Pharmaceuticals (SNSS) CFO Resigns - StreetInsider.com
www.streetinsider.com - April 14 at 12:29 PM |
| Sunesis Pharmaceuticals (SNSS) CFO Resigns
www.streetinsider.com - April 12 at 8:09 PM |
| Sunesis Pharmaceuticals (SNSS) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 12:41 PM |
| Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK ... - GlobeNewswire (press release)
globenewswire.com - April 3 at 8:27 AM |
| SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - March 27 at 7:05 PM |
 | Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin
us.rd.yahoo.com - March 22 at 8:18 AM |
| Sunesis Pharmaceuticals' (SNSS) CEO Daniel Swisher on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 7:53 PM |
| Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
us.rd.yahoo.com - March 9 at 7:53 PM |
| 7:05 am Sunesis Pharma beats by $0.01, beats on revs
us.rd.yahoo.com - March 9 at 7:53 PM |
| Q4 2016 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 9 at 7:53 PM |
| SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
biz.yahoo.com - March 9 at 7:53 PM |
| Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
feeds.benzinga.com - March 2 at 7:54 AM |
| Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
feeds.benzinga.com - March 1 at 7:16 AM |
| Sunesis Pharmaceuticals (SNSS) Presents at 19th Annual BIO CEO & Investor Conference
seekingalpha.com - February 15 at 6:07 AM |
| Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference
feeds.benzinga.com - February 6 at 7:42 AM |
Sunesis Pharmaceuticals (SNSS) Chart for Tuesday, October, 17, 2017
